Has Pedro Colon Hernandez, MD received payments from drug or device companies?

Yes. Drug and device makers reported $127,967 in general payments to Pedro Colon Hernandez, MD across 885 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Pedro Colon Hernandez, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Pedro Colon Hernandez, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Pedro Colon Hernandez, MD

Interventional Cardiology · Caguas, PRNPI 1659452415

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (40.7%), food and beverage and speaking fees — rather than concentrated in one kind of arrangement. Medtronic accounts for 66.9% of it on its own, with 15 other manufacturers making up the rest.

$127,967in general payments, 2019–2025

Across 885 payments — averaging $144.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Medtronic$86K
Abbott$28K
Edwards Lifesciences$8K
Terumo Medical Corporation$4K
Boston Scientific$1K
W. L. Gore & Associates, Inc.$933
plus $713 from 10 others

$852,456in research payments, 2019–2025

Across 12 payments — averaging $71,038 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

AstraZeneca$572K
Astrazeneca UK Limited$270K
Merck$6K
Medtronic$5K

What the payments were for

Consulting fees$52,14641%
Speaking & faculty fees$27,48421%
Travel & lodging$20,15016%
Food & beverage$28,18522%
Education$20%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Medtronic(2 entities)	439	$85,649
Abbott	172	$28,166
Edwards Lifesciences	148	$7,523
Terumo Medical Corporation	3	$3,651
Boston Scientific	82	$1,332
W. L. Gore & Associates, Inc.	13	$933
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)	13	$209
Johnson & Johnson	5	$164
Actelion Pharmaceuticals US, Inc.	1	$125
Merck	1	$61
E.r. Squibb & Sons, L.L.C.	2	$37
Inari Medical, Inc.	2	$34
Abiomed	1	$26
AstraZeneca	1	$20
Chiesi USA, Inc.	1	$20
Stryker	1	$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

CoreValve Evolut$21,971
COREVALVE EVOLUT R$10,988
PORTICO$7,657
MitraClip$5,038
Mitra Clip system$4,412
Optitorque$3,550
Heartrail$3,550
Glidesheath$3,550
GlideWire$3,550
Omnilink Elite vascular stent system$2,500
ABSOLUTE PRO$2,500
PASCAL$2,053
Resolute$712
Optis Coronary Imaging System$631
MitraClip System$453
SYMPLICITY G3$437
GORE CARDIOFORM Septal Occluder$428
Perclose ProGlide suture mediated closure system$421
Micra$395
Xience V coronary stent system$328

How this compares

$127,967 in reported general payments places this provider in the 80th percentile of 39 interventional cardiology providers in Puerto Rico.

See all interventional cardiology providers in Puerto Rico →

Medicare billing

Part B allowed, 2024

$16,491

Medicare patients

Services billed

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
ClopidogrelClopidogrel Bisulfate	326	$3,518

Paid to pharmacies, not to this prescriber.

Other interventional cardiology in Caguas

See the full list for Puerto Rico →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →